Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sequential hormone therapy for advanced breast cancer.

J H Von Roenn1, P D Bonomi, M Gale

  • 1Department of Medicine, Northwestern University, Chicago, IL 60611.

Seminars in Oncology
|April 1, 1988
PubMed
Summary

Sequential hormone therapy for advanced breast cancer shows promise. Receptor-positive patients are more likely to respond to subsequent treatments, suggesting a role for further hormonal trials in advanced breast cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correlates of HIV-1 control after combination immunotherapy.

Nature·2025
Same author

Implementation strategies to support pre-exposure prophylaxis for HIV prevention care for cisgender women in federally-funded family planning clinics in Atlanta, Georgia.

Frontiers in reproductive health·2025
Same author

Combination immunotherapy induces post-intervention control of HIV.

Research square·2025
Same author

Publisher Correction: Brain charts for the human lifespan.

Nature·2022
Same author

Brain charts for the human lifespan.

Nature·2022
Same author

A retrospective study of tuberculosis outcomes in Gulf Province, Papua New Guinea.

Public health action·2019

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Sequential hormone therapy is a viable option for advanced breast cancer, offering prolonged disease control.
  • Predictors for response to sequential hormone therapy remain largely unidentified.
  • Estrogen receptor (ER) and progesterone receptor (PgR) status are key factors in breast cancer treatment decisions.

Purpose of the Study:

  • To identify predictors of response to sequential hormone therapy in postmenopausal women with advanced or recurrent breast cancer.
  • To evaluate the effectiveness of sequential megestrol acetate and tamoxifen therapy.
  • To determine if receptor status influences treatment outcomes.

Main Methods:

  • A cohort of 60 postmenopausal women with advanced/recurrent breast cancer received sequential megestrol acetate and tamoxifen.

Related Experiment Videos

  • Response rates to first- and second-line hormonal therapies were calculated.
  • Statistical analyses (Chi-square, Fisher exact probability) were used to assess associations between response and various clinical factors, including receptor status.

    • Main Results:

    • The overall response rate to first-line therapy was 28%.
    • The response rate to second-line therapy was 25%.
    • Patients with receptor-positive tumors showed a significantly higher response rate to sequential hormonal therapies. All responders to second-line therapy were ER- and PgR-positive.

    Conclusions:

    • Estrogen receptor and progesterone receptor positivity are significant predictors of response to sequential hormone therapy in advanced breast cancer.
    • Patients who do not respond to initial hormone therapy may still benefit from a second hormonal trial if their tumors are ER- and PgR-positive.